Another FD‐targeted therapeutic program is conducted by a different pharmaceutical company, which brought in the clinic BCX9930 within two phase II studies in untreated PNH patients or in PNH patients with inadequate response to C5 inhibitors. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.